Effects of carbamazepine and sodium valproate on efficacy, cognitive function and uric acid in epileptic patients with first generalized seizure

Objective: To investigate the effects of carbamazepine and sodium valproate on efficacy, cognitive function and uric acid in epileptic patients with first generalized seizure. Methods: 120 epilepsy patients with first generalized seizure who admitted to our hospital from March 2017 to March 2019, were selected and randomly divided into carbamazepine-group and sodium valproate-group, with 60 objects in each group. Both groups of patients received medication for one year. Subsequently, the changes in clinical efficacy, cognitive function, and blood uric acid of the two groups of patients 1 year after treatment were compared, and the correlation between blood uric acid and cognitive function was analyzed between the two groups. Results: The two groups had statistically insignificant difference in the total effective rate (P>0.05). The cognitive function scores of the two groups after 6 months and 1 year of treatment were critically higher than those before treatment (P<0.05), and the comparison of cognitive function and blood uric acid degree between groups before treatment, 6 months after treatment and 1 year after treatment had statistically insignificant difference (P>0.05). There was a significant positive correlation between Mini-mental State Examination (MMSE) score of cognitive function and level of blood uric acid in patients with epilepsy (r=0.279, P=0.012). Conclusion: Both carbamazepine and valproate can effectively improve the cognitive function of patients with first generalized seizure, and the two medications have similar clinical efficacy. Patient's blood uric acid level increases after treatment, and there is a affirmative relationship between blood uric acid level and cognitive function of patients.